These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31413581)

  • 1. The clinical significance of statins-macrolides interaction: comprehensive review of in vivo studies, case reports, and population studies.
    Abu Mellal A; Hussain N; Said AS
    Ther Clin Risk Manag; 2019; 15():921-936. PubMed ID: 31413581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction potential between clarithromycin and individual statins-A systematic review.
    Hougaard Christensen MM; Bruun Haastrup M; Øhlenschlaeger T; Esbech P; Arnspang Pedersen S; Bach Dunvald AC; Bjerregaard Stage T; Pilsgaard Henriksen D; Thestrup Pedersen AJ
    Basic Clin Pharmacol Toxicol; 2020 Apr; 126(4):307-317. PubMed ID: 31628882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Metabolic interactions with statins].
    Molden E; Asberg A
    Tidsskr Nor Laegeforen; 2001 Jan; 121(2):189-93. PubMed ID: 11475198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
    Williams D; Feely J
    Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study.
    Patel AM; Shariff S; Bailey DG; Juurlink DN; Gandhi S; Mamdani M; Gomes T; Fleet J; Hwang YJ; Garg AX
    Ann Intern Med; 2013 Jun; 158(12):869-76. PubMed ID: 23778904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin safety and drug interactions: clinical implications.
    Bottorff MB
    Am J Cardiol; 2006 Apr; 97(8A):27C-31C. PubMed ID: 16581325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death.
    Mesgarpour B; Gouya G; Herkner H; Reichardt B; Wolzt M
    Lipids Health Dis; 2015 Oct; 14():131. PubMed ID: 26497728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population.
    Bakhai A; Rigney U; Hollis S; Emmas C
    Pharmacoepidemiol Drug Saf; 2012 May; 21(5):485-93. PubMed ID: 22237927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of potential drug interactions in co-prescription of statins and macrolide antibiotics in Croatia during the 14 year period.
    Grgurević D; Grgurević J; Vrca VB; Marušić S; Marinović I; Grgurević AB
    Pharmazie; 2021 Jun; 76(6):272-278. PubMed ID: 34078522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases.
    Ming EE; Davidson MH; Gandhi SK; Marotti M; Miles CG; Ke X; McKenney JM
    J Clin Lipidol; 2008 Dec; 2(6):453-63. PubMed ID: 21291779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
    Neuvonen PJ; Niemi M; Backman JT
    Clin Pharmacol Ther; 2006 Dec; 80(6):565-81. PubMed ID: 17178259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin-associated incident diabetes: a literature review.
    Park ZH; Juska A; Dyakov D; Patel RV
    Consult Pharm; 2014; 29(5):317-34. PubMed ID: 24849689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin safety: a systematic review.
    Law M; Rudnicka AR
    Am J Cardiol; 2006 Apr; 97(8A):52C-60C. PubMed ID: 16581329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant use of statins and macrolide antibiotics and risk of serious renal events: A nationwide cohort study.
    Lund M; Svanström H; Pasternak B; Hviid A; Melbye M
    Int J Cardiol; 2018 Oct; 269():310-316. PubMed ID: 30072148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of ADRs associated with lipid-lowering agents recorded in the Department of Internal Medicine, University Hospital, Jena.
    Hippius M; Farker K; Helble S; Hoffmann A
    Int J Clin Pharmacol Ther; 2002 Mar; 40(3):97-101. PubMed ID: 11911604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2007 Feb; 99(3):379-81. PubMed ID: 17261402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4.
    Li DQ; Kim R; McArthur E; Fleet JL; Bailey DG; Juurlink D; Shariff SZ; Gomes T; Mamdani M; Gandhi S; Dixon S; Garg AX
    CMAJ; 2015 Feb; 187(3):174-180. PubMed ID: 25534598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.